Inferior vena cava bypass for the treatment of obliterative hepatocavopathy with five-year follow-up

Javier E. Anaya-Ayala, Brett A. Johnson, Christopher J. Smolock, Mark G. Davies, Eric K. Peden

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Inferior vena cava (IVC) thrombosis at its hepatic portion (also known as obliterative hepatocavopathy [OH]), in the absence of systemic or local diseases such as vasculitis, coagulopathy, infection and malignancy, is a rare event. We report the case of a 25-yearold woman with progressive abdominal pain and leg edema after exercise. Imaging showed congestive liver and IVC occlusion at the intrahepatic portion. A liver biopsy demonstrated portal congestion without evidence of fibrosis; after unsuccessful percutaneous attempts for recanalization, consideration was given to liver transplantation with IVC reconstruction versus IVC bypass. Due to the presence of preserved liver function, an externally supported 16-mm ringed polytetrafluoroethylene graft was used to bypass from the suprarenal IVC to the suprahepatic IVC. At five years, she remains symptom-free, with normal liver function and a patent graft on systemic anticoagulation. This report highlights the successful surgical management of a patient with OH with a thick membrane. It supports other published proposals that this entity differs significantly from classic Budd.Chiari syndrome with thrombosis that affects only the hepatic veins and, thus, OH should be approached and managed differently.

Original languageEnglish (US)
Pages (from-to)282-286
Number of pages5
JournalVascular
Volume19
Issue number5
DOIs
StatePublished - Oct 1 2011
Externally publishedYes

Keywords

  • Budd-Chiari syndrome
  • Infra-suprahepatic inferior vena cava bypass
  • Obliterative hepatocavopathy

ASJC Scopus subject areas

  • Surgery
  • Radiology Nuclear Medicine and imaging
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Inferior vena cava bypass for the treatment of obliterative hepatocavopathy with five-year follow-up'. Together they form a unique fingerprint.

Cite this